From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy
Abstract In the past decades, Chimeric Antigen Receptor (CAR)-T cell therapy has achieved remarkable success, leading to the approval of six therapeutic products for haematological malignancies. Recently, the therapeutic potential of this therapy has also been demonstrated in non-tumoral diseases. C...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-024-06052-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559127351885824 |
|---|---|
| author | E. Pinto L. Lione M. Compagnone M. Paccagnella E. Salvatori M. Greco V. Frezza E. Marra L. Aurisicchio G. Roscilli A. Conforti |
| author_facet | E. Pinto L. Lione M. Compagnone M. Paccagnella E. Salvatori M. Greco V. Frezza E. Marra L. Aurisicchio G. Roscilli A. Conforti |
| author_sort | E. Pinto |
| collection | DOAJ |
| description | Abstract In the past decades, Chimeric Antigen Receptor (CAR)-T cell therapy has achieved remarkable success, leading to the approval of six therapeutic products for haematological malignancies. Recently, the therapeutic potential of this therapy has also been demonstrated in non-tumoral diseases. Currently, the manufacturing process to produce clinical-grade CAR-T cells is complex, time-consuming, and highly expensive. It involves multiple steps, including the collection of T cells from patients or healthy donors, in vitro engineering and expansion, and finally reinfusion into patients. Therefore, despite the impressive clinical outcomes, ex vivo manufacturing process makes CAR-T cells out of reach for many cancer patients. Direct in vivo engineering of T cells could be a more rapid solution able to circumvent both the complexity and the costs associated with ex vivo manufactured CAR-T cells. This novel approach allows to completely eliminate ex vivo cell manipulation and expansion while producing therapeutic cell populations directly in vivo. To date, several studies have demonstrated the feasibility of in vivo T cell reprogramming, by employing injectable viral- or nanocarrier-based delivery platforms in tumour animal models. Additionally, in vivo production of CAR-T cells might reduce the incidence, or at least the severity, of systemic toxicities frequently occurring with ex vivo produced CAR-T cells, such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. In this review, we highlight the challenges associated with the current ex vivo manufacturing protocols and review the latest progresses in the emerging field of in vivo CAR-T therapy, by comparing the various platforms so far investigated. Moreover, we offer an overview of the advantages deriving from in vivo reprogramming of other immune cell types, such as Natural Killer and macrophages, with CAR constructs. |
| format | Article |
| id | doaj-art-2fbaa1a8cffe4d84b4aecb32724c8352 |
| institution | Kabale University |
| issn | 1479-5876 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj-art-2fbaa1a8cffe4d84b4aecb32724c83522025-01-05T12:44:37ZengBMCJournal of Translational Medicine1479-58762025-01-0123111610.1186/s12967-024-06052-3From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapyE. Pinto0L. Lione1M. Compagnone2M. Paccagnella3E. Salvatori4M. Greco5V. Frezza6E. Marra7L. Aurisicchio8G. Roscilli9A. Conforti10Evvivax BiotechTakis BiotechEvvivax BiotechTakis BiotechTakis BiotechTakis BiotechTakis BiotechTakis BiotechEvvivax BiotechTakis BiotechEvvivax BiotechAbstract In the past decades, Chimeric Antigen Receptor (CAR)-T cell therapy has achieved remarkable success, leading to the approval of six therapeutic products for haematological malignancies. Recently, the therapeutic potential of this therapy has also been demonstrated in non-tumoral diseases. Currently, the manufacturing process to produce clinical-grade CAR-T cells is complex, time-consuming, and highly expensive. It involves multiple steps, including the collection of T cells from patients or healthy donors, in vitro engineering and expansion, and finally reinfusion into patients. Therefore, despite the impressive clinical outcomes, ex vivo manufacturing process makes CAR-T cells out of reach for many cancer patients. Direct in vivo engineering of T cells could be a more rapid solution able to circumvent both the complexity and the costs associated with ex vivo manufactured CAR-T cells. This novel approach allows to completely eliminate ex vivo cell manipulation and expansion while producing therapeutic cell populations directly in vivo. To date, several studies have demonstrated the feasibility of in vivo T cell reprogramming, by employing injectable viral- or nanocarrier-based delivery platforms in tumour animal models. Additionally, in vivo production of CAR-T cells might reduce the incidence, or at least the severity, of systemic toxicities frequently occurring with ex vivo produced CAR-T cells, such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. In this review, we highlight the challenges associated with the current ex vivo manufacturing protocols and review the latest progresses in the emerging field of in vivo CAR-T therapy, by comparing the various platforms so far investigated. Moreover, we offer an overview of the advantages deriving from in vivo reprogramming of other immune cell types, such as Natural Killer and macrophages, with CAR constructs.https://doi.org/10.1186/s12967-024-06052-3CAR T cellManufacturingT cell engineering |
| spellingShingle | E. Pinto L. Lione M. Compagnone M. Paccagnella E. Salvatori M. Greco V. Frezza E. Marra L. Aurisicchio G. Roscilli A. Conforti From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy Journal of Translational Medicine CAR T cell Manufacturing T cell engineering |
| title | From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy |
| title_full | From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy |
| title_fullStr | From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy |
| title_full_unstemmed | From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy |
| title_short | From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy |
| title_sort | from ex vivo to in vivo chimeric antigen t cells manufacturing new horizons for car t cell based therapy |
| topic | CAR T cell Manufacturing T cell engineering |
| url | https://doi.org/10.1186/s12967-024-06052-3 |
| work_keys_str_mv | AT epinto fromexvivotoinvivochimericantigentcellsmanufacturingnewhorizonsforcartcellbasedtherapy AT llione fromexvivotoinvivochimericantigentcellsmanufacturingnewhorizonsforcartcellbasedtherapy AT mcompagnone fromexvivotoinvivochimericantigentcellsmanufacturingnewhorizonsforcartcellbasedtherapy AT mpaccagnella fromexvivotoinvivochimericantigentcellsmanufacturingnewhorizonsforcartcellbasedtherapy AT esalvatori fromexvivotoinvivochimericantigentcellsmanufacturingnewhorizonsforcartcellbasedtherapy AT mgreco fromexvivotoinvivochimericantigentcellsmanufacturingnewhorizonsforcartcellbasedtherapy AT vfrezza fromexvivotoinvivochimericantigentcellsmanufacturingnewhorizonsforcartcellbasedtherapy AT emarra fromexvivotoinvivochimericantigentcellsmanufacturingnewhorizonsforcartcellbasedtherapy AT laurisicchio fromexvivotoinvivochimericantigentcellsmanufacturingnewhorizonsforcartcellbasedtherapy AT groscilli fromexvivotoinvivochimericantigentcellsmanufacturingnewhorizonsforcartcellbasedtherapy AT aconforti fromexvivotoinvivochimericantigentcellsmanufacturingnewhorizonsforcartcellbasedtherapy |